Zenas Biopharma’s lead autoimmune drug has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 multiple sclerosis (MS) study.  | Zenas Biopharma’s lead autoimmune drug ...

Scientists have found blood protein signals that may flag multiple sclerosis up to seven years before symptoms begin.

People with multiple sclerosis (MS) have altered levels of several key bacteria in the mouth, a new study reports.

"Multiple sclerosis: three trials to watch" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

The first patient has been dosed in a Phase 1 trial testing the experimental CAR T-cell therapy obecabtagene autoleucel for progressive MS.

With ads everywhere for pro- or pre-biotic foods and supplements, most people are familiar with the gut microbiome—the ...

UCSF study finds MS starts damaging the brain years before symptoms appear. Early immune attack on myelin and key proteins ...

Radiomics offers improved assessment of spinal cord pathology in MS, surpassing conventional MRI in precision and sensitivity ...

By the time patients start seeking care for multiple sclerosis (MS), the disease has already been damaging their brains for ...

A new study indicates that amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) have an extremely high geographic association, even after controlling for race, gender, wealth, latitude, and ...

MOG-IgG positivity is rare in MS patients, complicating diagnosis and treatment, especially in Asian populations with lower ...

An analysis of data from phase 3 randomized controlled trials showed that among individuals with comparable disease duration, inflammatory disease activity was significantly lower in older trial ...